Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

4 clinical studies listed.

Filters:

mRNA Vaccine

Tundra lists 4 mRNA Vaccine clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

NOT YET RECRUITING

NCT07418229

Study to Evaluate the Safety of a Lyophilized RSV mRNA Vaccine

To evaluate the safety of Sinovac RSV mRNA among participants aged ≥18 years

Gender: All

Ages: 18 Years - Any

Updated: 2026-02-18

1 state

RSV
mRNA Vaccine
RECRUITING

NCT07400003

Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine

This clinical trial included two parts, Part A and Part B. The goal of Part A is to evaluate the safety and preliminary immunogenicity of the lyophilized herpes zoster virus mRNA vaccine (HZ mRNA vaccine) in healthy populations aged 40 years and older. The goal of Part B is to select the optimal dosage and schedule in healthy populations aged 50 years and older to support next further study.

Gender: All

Ages: 40 Years - Any

Updated: 2026-02-10

Herpes Zoster
mRNA Vaccine
RECRUITING

NCT07100210

A Clinical Trial Evaluating IL-22BP/LNP Compound in Refractory Malignant Solid Tumors for Safety, Tolerability and Activity

This study aims to investigate the safety and efficacy of the IL-22BP/LNP compound in patients with refractory malignant solid tumors, such as advanced soft tissue sarcoma, advanced head and neck squamous cell carcinoma, and malignant melanoma, who have failed second-line treatment, have advanced recurrence or metastatic malignant solid tumors.

Gender: All

Ages: 18 Years - 70 Years

Updated: 2025-12-29

1 state

Refractory Malignant Solid Tumors
mRNA Vaccine
Interleukin
RECRUITING

NCT07040943

Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.

This study aims to investigate the safety and efficacy of the IL-22BP in patients with refractory malignant solid tumors.

Gender: All

Ages: 18 Years - 70 Years

Updated: 2025-07-01

1 state

Refractory Malignant Solid Tumors
mRNA Vaccine
Interleukin